Janos Meszaros

Janos Meszaros

Auto-generated profile, based on publicly available information

Janos Meszaros

Division of Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MGMelanie Goisauf
Melanie Goisauf
MAMónica Cano Abadía
Mónica Cano Abadía
KAKaya Akyüz
Kaya Akyüz
MBMaciej Bobowicz
Maciej Bobowicz
ABAlena Buyx
Alena Buyx
JMJanos Meszaros
Janos Meszaros
Trustworthiness has become a key concept for the ethical development and application of artificial intelligence (AI) in medicine. Various guidelines have formulated key principles, such as fairness, robustness, and explainability, as essential components to achieve trustworthy AI. However, conceptualizations of trustworthy AI often emphasize technical requirements and computational solutions, frequently overlooking broader aspects of fairness and potential biases. These include not only algorithmic bias but also human, institutional, social, and societal factors, which are critical to foster AI systems that are both ethically sound and socially responsible. This viewpoint article presents an interdisciplinary approach to analyzing trust in AI and trustworthy AI within the medical context, focusing on (1) social sciences and humanities conceptualizations and legal perspectives on trust and (2) their implications for trustworthy AI in health care. It focuses on real-world challenges in medicine that are often underrepresented in theoretical discussions to propose a more practice-oriented understanding. Insights were gathered from an interdisciplinary workshop with experts from various disciplines involved in the development and application of medical AI, particularly in oncological imaging and genomics, complemented by theoretical approaches related to trust in AI. Results emphasize that, beyond common issues of bias and fairness, knowledge and human involvement are essential for trustworthy AI. Stakeholder engagement throughout the AI life cycle emerged as crucial, supporting a human- and multicentered framework for trustworthy AI implementation. Findings emphasize that trust in medical AI depends on providing meaningful, user-oriented information and balancing knowledge with acceptable uncertainty. Experts highlighted the importance of confidence in the tool's functionality, specifically that it performs as expected. Trustworthiness was shown to be not a feature but rather a relational process, involving humans, their expertise, and the broader social or institutional contexts in which AI tools operate. Trust is dynamic, shaped by interactions among individuals, technologies, and institutions, and ultimately centers on people rather than tools alone. Tools are evaluated based on reliability and credibility, yet trust fundamentally relies on human connections. The article underscores the development of AI tools that are not only technically sound but also ethically robust and broadly accepted by end users, contributing to more effective and equitable AI-mediated health care. Findings highlight that building AI trustworthiness in health care requires a human-centered, multistakeholder approach with diverse and inclusive engagement. To promote equity, we recommend that AI development teams involve all relevant stakeholders at every stage of the AI lifecycle—from conception, technical development, clinical validation, and real-world deployment.

1 June 2019 in Medical Law International
Verified
Journal Article
Closed access
PDF file
JMJanos Meszaros
Janos Meszaros
CHChih-Hsing Ho
Chih-Hsing Ho
After the failure of the care.data programme, a revised opt-out system has been introduced for British citizens to protect their health data from 2018. However, there are several exemptions from the previous and the revised opt-out systems, some of which are overly broad. For instance, the opt-outs may be completely ignored in the case of ‘anonymised’ data. The data protection terminology in the United Kingdom is slightly different from that in the European Union, and the key issue is that the terms are not used consistently, even in the most important documents and guidelines. This situation may lead to a weak opt-out system with transparency issues, which might erode public trust and lead to a repeat of the care.data failure. Furthermore, the United Kingdom intends to comply with the General Data Protection Regulation after Brexit, thus these differences may cause compatibility issues in the future.

13 June 2023 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
LDLaura Drechsler
Laura Drechsler
AEAbdullah Elbi
Abdullah Elbi
EKEls Kindt
Els Kindt
EKEyup Kun
Eyup Kun
JMJanos Meszaros
Janos Meszaros
KVKoen Vranckaert
Koen Vranckaert
On 13 December 2022 the European Commission published a draft for a third arrangement for data transfers to the US – the Data Privacy Framework (DPF). In this Working Paper, we want to assess whether the draft DPF has a chance of succeeding before the Court of Justice of the EU (CJEU). To this end, we first explain and subsequently compare the provisions of the draft DPF with those of its predecessors, the Safe Harbor Agreement and the Privacy Shield. Our assessment will be holistic, it will consider all the provisions of the draft DPF in order to provide a clear picture of what rules are envisioned within the draft DPF and how these rules differ from earlier versions. In a second step, we will assess whether the draft DPF fulfils the legal requirements for data transfers of the CJEU, GDPR and the Charter for both its general rules and its safeguards for governmental access In our concluding remarks, we demonstrate that the draft DPF is not the leap forward one would expect after two invalidations by the CJEU. Key weaknesses include the provisions on governmental access, especially the question of effective legal remedies, but also the general provisions on ensuring the protection of personal data transferred (e.g. in terms of data subject rights and legal remedies).

13 January 2025 in JMIR Preprints
Verified
Preprint
Open access
MGMelanie Goisauf
Melanie Goisauf
MAMónica Cano Abadía
Mónica Cano Abadía
KAKaya Akyüz
Kaya Akyüz
MBMaciej Bobowicz
Maciej Bobowicz
ABAlena Buyx
Alena Buyx
JMJanos Meszaros
Janos Meszaros
UNSTRUCTURED Trustworthiness has become a key concept for the ethical development and application of artificial intelligence (AI) in medicine. Various guidelines have formulated key principles, such as fairness, robustness, and explainability, as essential components to achieve trustworthy AI. However, conceptualizations of trustworthy AI often emphasize technical requirements and computational solutions, frequently overlooking broader aspects of fairness and potential biases. These include not only algorithmic bias but also human, institutional, social, and societal factors, which are critical to foster AI systems that are both ethically sound and socially responsible. This viewpoint article presents an interdisciplinary approach to analyzing trust in AI and trustworthy AI within the medical context, focusing on (1) social sciences and humanities conceptualizations and legal perspectives on trust and (2) their implications for trustworthy AI in health care. It focuses on real-world challenges in medicine that are often underrepresented in theoretical discussions to propose a more practice-oriented understanding. Insights were gathered from an interdisciplinary workshop with experts from various disciplines involved in the development and application of medical AI, particularly in oncological imaging and genomics, complemented by theoretical approaches related to trust in AI. Results emphasize that, beyond common issues of bias and fairness, knowledge and human involvement are essential for trustworthy AI. Stakeholder engagement throughout the AI life cycle emerged as crucial, supporting a human- and multicentered framework for trustworthy AI implementation. Findings emphasize that trust in medical AI depends on providing meaningful, user-oriented information and balancing knowledge with acceptable uncertainty. Experts highlighted the importance of confidence in the tool's functionality, specifically that it performs as expected. Trustworthiness was shown to be not a feature but rather a relational process, involving humans, their expertise, and the broader social or institutional contexts in which AI tools operate. Trust is dynamic, shaped by interactions among individuals, technologies, and institutions, and ultimately centers on people rather than tools alone. Tools are evaluated based on reliability and credibility, yet trust fundamentally relies on human connections. The article underscores the development of AI tools that are not only technically sound but also ethically robust and broadly accepted by end users, contributing to more effective and equitable AI-mediated health care. Findings highlight that building AI trustworthiness in health care requires a human-centered, multistakeholder approach with diverse and inclusive engagement. To promote equity, we recommend that AI development teams involve all relevant stakeholders at every stage of the AI lifecycle—from conception, technical development, clinical validation, and real-world deployment.